Open AccessPsoriasis in an Asian patient with atopic dermatitis treated with dupilumab
Author(s) -
Mitsuru Ishibashi,
Ritsuko Koga,
Eriko Adachi,
Yuna Yamagami,
Masami Ichia,
Yoshiaki Yoshikawa
Publication year - 2021
Publication title -
trends in immunotherapy
Language(s) - English
Resource type - Journals
ISSN - 2573-5985
DOI - 10.24294/ti.v5.i1.1286
Subject(s) - dupilumab , atopic dermatitis , psoriasis , phenotype , immunology , medicine , interleukin 23 , monoclonal antibody , interleukin 17 , inflammation , blockade , dermatology , receptor , antibody , biology , gene , biochemistry
Dupilumab is a monoclonal antibody against the alpha subunit of the interleukin (IL)-4 receptor that inhibits IL-4 and IL-13 signaling, which plays a central role in Th2 inflammation in AD.Here, we report the first Asian case of psoriasis unexpectedly induced by dupilumab therapy for AD. Compared with European and American AD phenotype, Asian AD phenotype is characterized by changes in the psoriasiform phenotype, associating with higher Th17 activation. The blockade of IL-4/IL-13 signaling by dupilumab may induce psoriasis eruption corresponding to shift from a Th2- to Th17- mediated inflammatory response in the skin.